Multimodality vaccination against clade C SHIV

Partial protection against mucosal challenges with a heterologous tier 2 virus

Samir K. Lakhashe, Siddappa Nagadenahalli Byrareddy, Mingkui Zhou, Barbara C. Bachler, Girish Hemashettar, Shiu Lok Hu, Francois Villinger, James G. Else, Shannon Stock, Sandra J. Lee, Diego A. Vargas-Inchaustegui, Egidio Brocca Cofano, Marjorie Robert-Guroff, Welkin E. Johnson, Victoria R. Polonis, Donald N. Forthal, Erwann P. Loret, Robert A. Rasmussen, Ruth M. Ruprecht

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We sought to test whether vaccine-induced immune responses could protect rhesus macaques (RMs) against upfront heterologous challenges with an R5 simian-human immunodeficiency virus, SHIV-2873Nip. This SHIV strain exhibits many properties of transmitted HIV-1, such as tier 2 phenotype (relatively difficult to neutralize), exclusive CCR5 tropism, and gradual disease progression in infected RMs. Since no human AIDS vaccine recipient is likely to encounter an HIV-1 strain that exactly matches the immunogens, we immunized the RMs with recombinant Env proteins heterologous to the challenge virus. For induction of immune responses against Gag, Tat, and Nef, we explored a strategy of immunization with overlapping synthetic peptides (OSP). The immune responses against Gag and Tat were finally boosted with recombinant proteins. The vaccinees and a group of ten control animals were given five low-dose intrarectal (i.r.) challenges with SHIV-2873Nip. All controls and seven out of eight vaccinees became systemically infected; there was no significant difference in viremia levels of vaccinees vs. controls. Prevention of viremia was observed in one vaccinee which showed strong boosting of virus-specific cellular immunity during virus exposures. The protected animal showed no challenge virus-specific neutralizing antibodies in the TZM-bl or A3R5 cell-based assays and had low-level ADCC activity after the virus exposures. Microarray data strongly supported a role for cellular immunity in the protected animal. Our study represents a case of protection against heterologous tier 2 SHIV-C by vaccine-induced, virus-specific cellular immune responses.

Original languageEnglish (US)
Pages (from-to)6527-6536
Number of pages10
JournalVaccine
Volume32
Issue number48
DOIs
StatePublished - Nov 12 2014

Fingerprint

Vaccination
vaccination
Viruses
viruses
Macaca mulatta
Cellular Immunity
cell-mediated immunity
Viremia
viremia
immune response
vaccines
Human immunodeficiency virus 1
Recombinant Proteins
recombinant proteins
HIV-1
Vaccines
env Gene Products
Antibody-Dependent Cell Cytotoxicity
AIDS Vaccines
Simian Immunodeficiency Virus

Keywords

  • ADCC
  • Cellular immunity
  • HIV vaccine
  • Heterologous tier 2 virus
  • Rhesus monkey
  • SHIV-C

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Multimodality vaccination against clade C SHIV : Partial protection against mucosal challenges with a heterologous tier 2 virus. / Lakhashe, Samir K.; Byrareddy, Siddappa Nagadenahalli; Zhou, Mingkui; Bachler, Barbara C.; Hemashettar, Girish; Hu, Shiu Lok; Villinger, Francois; Else, James G.; Stock, Shannon; Lee, Sandra J.; Vargas-Inchaustegui, Diego A.; Cofano, Egidio Brocca; Robert-Guroff, Marjorie; Johnson, Welkin E.; Polonis, Victoria R.; Forthal, Donald N.; Loret, Erwann P.; Rasmussen, Robert A.; Ruprecht, Ruth M.

In: Vaccine, Vol. 32, No. 48, 12.11.2014, p. 6527-6536.

Research output: Contribution to journalArticle

Lakhashe, SK, Byrareddy, SN, Zhou, M, Bachler, BC, Hemashettar, G, Hu, SL, Villinger, F, Else, JG, Stock, S, Lee, SJ, Vargas-Inchaustegui, DA, Cofano, EB, Robert-Guroff, M, Johnson, WE, Polonis, VR, Forthal, DN, Loret, EP, Rasmussen, RA & Ruprecht, RM 2014, 'Multimodality vaccination against clade C SHIV: Partial protection against mucosal challenges with a heterologous tier 2 virus', Vaccine, vol. 32, no. 48, pp. 6527-6536. https://doi.org/10.1016/j.vaccine.2014.08.065
Lakhashe, Samir K. ; Byrareddy, Siddappa Nagadenahalli ; Zhou, Mingkui ; Bachler, Barbara C. ; Hemashettar, Girish ; Hu, Shiu Lok ; Villinger, Francois ; Else, James G. ; Stock, Shannon ; Lee, Sandra J. ; Vargas-Inchaustegui, Diego A. ; Cofano, Egidio Brocca ; Robert-Guroff, Marjorie ; Johnson, Welkin E. ; Polonis, Victoria R. ; Forthal, Donald N. ; Loret, Erwann P. ; Rasmussen, Robert A. ; Ruprecht, Ruth M. / Multimodality vaccination against clade C SHIV : Partial protection against mucosal challenges with a heterologous tier 2 virus. In: Vaccine. 2014 ; Vol. 32, No. 48. pp. 6527-6536.
@article{9ac55b91a81e415195a4761e131d98e0,
title = "Multimodality vaccination against clade C SHIV: Partial protection against mucosal challenges with a heterologous tier 2 virus",
abstract = "We sought to test whether vaccine-induced immune responses could protect rhesus macaques (RMs) against upfront heterologous challenges with an R5 simian-human immunodeficiency virus, SHIV-2873Nip. This SHIV strain exhibits many properties of transmitted HIV-1, such as tier 2 phenotype (relatively difficult to neutralize), exclusive CCR5 tropism, and gradual disease progression in infected RMs. Since no human AIDS vaccine recipient is likely to encounter an HIV-1 strain that exactly matches the immunogens, we immunized the RMs with recombinant Env proteins heterologous to the challenge virus. For induction of immune responses against Gag, Tat, and Nef, we explored a strategy of immunization with overlapping synthetic peptides (OSP). The immune responses against Gag and Tat were finally boosted with recombinant proteins. The vaccinees and a group of ten control animals were given five low-dose intrarectal (i.r.) challenges with SHIV-2873Nip. All controls and seven out of eight vaccinees became systemically infected; there was no significant difference in viremia levels of vaccinees vs. controls. Prevention of viremia was observed in one vaccinee which showed strong boosting of virus-specific cellular immunity during virus exposures. The protected animal showed no challenge virus-specific neutralizing antibodies in the TZM-bl or A3R5 cell-based assays and had low-level ADCC activity after the virus exposures. Microarray data strongly supported a role for cellular immunity in the protected animal. Our study represents a case of protection against heterologous tier 2 SHIV-C by vaccine-induced, virus-specific cellular immune responses.",
keywords = "ADCC, Cellular immunity, HIV vaccine, Heterologous tier 2 virus, Rhesus monkey, SHIV-C",
author = "Lakhashe, {Samir K.} and Byrareddy, {Siddappa Nagadenahalli} and Mingkui Zhou and Bachler, {Barbara C.} and Girish Hemashettar and Hu, {Shiu Lok} and Francois Villinger and Else, {James G.} and Shannon Stock and Lee, {Sandra J.} and Vargas-Inchaustegui, {Diego A.} and Cofano, {Egidio Brocca} and Marjorie Robert-Guroff and Johnson, {Welkin E.} and Polonis, {Victoria R.} and Forthal, {Donald N.} and Loret, {Erwann P.} and Rasmussen, {Robert A.} and Ruprecht, {Ruth M.}",
year = "2014",
month = "11",
day = "12",
doi = "10.1016/j.vaccine.2014.08.065",
language = "English (US)",
volume = "32",
pages = "6527--6536",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "48",

}

TY - JOUR

T1 - Multimodality vaccination against clade C SHIV

T2 - Partial protection against mucosal challenges with a heterologous tier 2 virus

AU - Lakhashe, Samir K.

AU - Byrareddy, Siddappa Nagadenahalli

AU - Zhou, Mingkui

AU - Bachler, Barbara C.

AU - Hemashettar, Girish

AU - Hu, Shiu Lok

AU - Villinger, Francois

AU - Else, James G.

AU - Stock, Shannon

AU - Lee, Sandra J.

AU - Vargas-Inchaustegui, Diego A.

AU - Cofano, Egidio Brocca

AU - Robert-Guroff, Marjorie

AU - Johnson, Welkin E.

AU - Polonis, Victoria R.

AU - Forthal, Donald N.

AU - Loret, Erwann P.

AU - Rasmussen, Robert A.

AU - Ruprecht, Ruth M.

PY - 2014/11/12

Y1 - 2014/11/12

N2 - We sought to test whether vaccine-induced immune responses could protect rhesus macaques (RMs) against upfront heterologous challenges with an R5 simian-human immunodeficiency virus, SHIV-2873Nip. This SHIV strain exhibits many properties of transmitted HIV-1, such as tier 2 phenotype (relatively difficult to neutralize), exclusive CCR5 tropism, and gradual disease progression in infected RMs. Since no human AIDS vaccine recipient is likely to encounter an HIV-1 strain that exactly matches the immunogens, we immunized the RMs with recombinant Env proteins heterologous to the challenge virus. For induction of immune responses against Gag, Tat, and Nef, we explored a strategy of immunization with overlapping synthetic peptides (OSP). The immune responses against Gag and Tat were finally boosted with recombinant proteins. The vaccinees and a group of ten control animals were given five low-dose intrarectal (i.r.) challenges with SHIV-2873Nip. All controls and seven out of eight vaccinees became systemically infected; there was no significant difference in viremia levels of vaccinees vs. controls. Prevention of viremia was observed in one vaccinee which showed strong boosting of virus-specific cellular immunity during virus exposures. The protected animal showed no challenge virus-specific neutralizing antibodies in the TZM-bl or A3R5 cell-based assays and had low-level ADCC activity after the virus exposures. Microarray data strongly supported a role for cellular immunity in the protected animal. Our study represents a case of protection against heterologous tier 2 SHIV-C by vaccine-induced, virus-specific cellular immune responses.

AB - We sought to test whether vaccine-induced immune responses could protect rhesus macaques (RMs) against upfront heterologous challenges with an R5 simian-human immunodeficiency virus, SHIV-2873Nip. This SHIV strain exhibits many properties of transmitted HIV-1, such as tier 2 phenotype (relatively difficult to neutralize), exclusive CCR5 tropism, and gradual disease progression in infected RMs. Since no human AIDS vaccine recipient is likely to encounter an HIV-1 strain that exactly matches the immunogens, we immunized the RMs with recombinant Env proteins heterologous to the challenge virus. For induction of immune responses against Gag, Tat, and Nef, we explored a strategy of immunization with overlapping synthetic peptides (OSP). The immune responses against Gag and Tat were finally boosted with recombinant proteins. The vaccinees and a group of ten control animals were given five low-dose intrarectal (i.r.) challenges with SHIV-2873Nip. All controls and seven out of eight vaccinees became systemically infected; there was no significant difference in viremia levels of vaccinees vs. controls. Prevention of viremia was observed in one vaccinee which showed strong boosting of virus-specific cellular immunity during virus exposures. The protected animal showed no challenge virus-specific neutralizing antibodies in the TZM-bl or A3R5 cell-based assays and had low-level ADCC activity after the virus exposures. Microarray data strongly supported a role for cellular immunity in the protected animal. Our study represents a case of protection against heterologous tier 2 SHIV-C by vaccine-induced, virus-specific cellular immune responses.

KW - ADCC

KW - Cellular immunity

KW - HIV vaccine

KW - Heterologous tier 2 virus

KW - Rhesus monkey

KW - SHIV-C

UR - http://www.scopus.com/inward/record.url?scp=84908582695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908582695&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2014.08.065

DO - 10.1016/j.vaccine.2014.08.065

M3 - Article

VL - 32

SP - 6527

EP - 6536

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 48

ER -